Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Receivables (2021 - 2026)

bioAffinity Technologies has reported Receivables over the past 6 years, most recently at $717732.0 for Q1 2026.

  • Quarterly Receivables fell 26.85% to $717732.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $717732.0 through Mar 2026, down 26.85% year-over-year, with the annual reading at $568257.0 for FY2025, 51.31% down from the prior year.
  • Receivables was $717732.0 for Q1 2026 at bioAffinity Technologies, up from $568257.0 in the prior quarter.
  • Over five years, Receivables peaked at $1.7 million in Q2 2024 and troughed at $9930.0 in Q3 2022.
  • The 5-year median for Receivables is $717732.0 (2026), against an average of $713956.7.
  • Year-over-year, Receivables skyrocketed 11109.91% in 2023 and then plummeted 74.26% in 2025.
  • A 5-year view of Receivables shows it stood at $20978.0 in 2022, then soared by 3910.04% to $841227.0 in 2023, then skyrocketed by 38.74% to $1.2 million in 2024, then crashed by 51.31% to $568257.0 in 2025, then rose by 26.3% to $717732.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Receivables are $717732.0 (Q1 2026), $568257.0 (Q4 2025), and $476133.0 (Q3 2025).